← Back to Screener
Vertex Pharmaceuticals Inc (VRTX)
Price$439.18
Favorite Metrics
Price vs S&P 500 (26W)0.92%
Price vs S&P 500 (4W)-10.81%
Market Capitalization$111.76B
P/E Ratio (Annual)28.27x
All Metrics
P/CF (Annual)30.78x
Book Value / Share (Quarterly)$73.49
P/TBV (Annual)6.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.35%
Cash Flow / Share (Quarterly)$12.57
Price vs S&P 500 (YTD)-7.06%
Gross Margin (TTM)86.24%
Net Profit Margin (TTM)32.94%
EPS (TTM)$15.33
10-Day Avg Trading Volume1.14M
EPS Excl Extra (TTM)$15.33
Revenue Growth (5Y)14.10%
EPS (Annual)$15.32
ROI (Annual)21.05%
Gross Margin (Annual)86.24%
Net Profit Margin (5Y Avg)26.58%
Cash / Share (Quarterly)$26.02
P/E Basic Excl Extra (TTM)28.27x
Revenue Growth QoQ (YoY)9.55%
EPS Growth (5Y)8.28%
P/E Normalized (Annual)28.27x
ROA (Last FY)15.42%
Revenue Growth TTM (YoY)8.90%
EBITD / Share (TTM)$16.97
ROE (5Y Avg)17.12%
Operating Margin (TTM)34.77%
Cash Flow / Share (Annual)$12.57
P/B Ratio5.99x
P/B Ratio (Quarterly)6.16x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)8.77x
Net Interest Coverage (TTM)72.37x
ROA (TTM)16.23%
EPS Growth QoQ (YoY)31.02%
EV / EBITDA (TTM)24.04x
EPS Incl Extra (Annual)$15.32
Current Ratio (Annual)2.90x
Quick Ratio (Quarterly)2.24x
3-Month Avg Trading Volume1.41M
52-Week Price Return-10.21%
EV / Free Cash Flow (Annual)32.96x
P/E Incl Extra (TTM)28.27x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$71.82
P/S Ratio (Annual)9.31x
Asset Turnover (Annual)0.47x
52-Week High$510.77
Operating Margin (5Y Avg)31.29%
EPS Excl Extra (Annual)$15.32
CapEx CAGR (5Y)10.99%
Tangible BV CAGR (5Y)17.01%
26-Week Price Return7.81%
Quick Ratio (Annual)2.27x
13-Week Price Return0.06%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)2.90x
Enterprise Value$105,256.64
Revenue / Share Growth (5Y)14.57%
Asset Turnover (TTM)0.49x
Book Value / Share Growth (5Y)17.07%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)1.14x
Pretax Margin (Annual)38.69%
Cash / Share (Annual)$26.02
3-Month Return Std Dev34.22%
Gross Margin (5Y Avg)87.10%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)7.01%
EBITDA Interim CAGR (5Y)7.02%
ROE (Last FY)21.18%
Net Interest Coverage (Annual)16.95x
EPS Basic Excl Extra (Annual)$15.32
P/FCF (TTM)34.99x
Receivables Turnover (TTM)6.55x
EV / Free Cash Flow (TTM)32.96x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$15.33
Receivables Turnover (Annual)6.55x
ROI (TTM)22.63%
P/S Ratio (TTM)9.31x
Pretax Margin (5Y Avg)33.75%
Revenue / Share (Annual)$46.52
Tangible BV / Share (Annual)$71.56
Forward P/E22.91x
Free OCF CAGR (5Y)1.30%
Price vs S&P 500 (52W)-44.84%
P/E Ratio (TTM)28.27x
Year-to-Date Return-3.13%
5-Day Price Return-1.15%
EPS Normalized (Annual)$15.32
ROA (5Y Avg)12.94%
Net Profit Margin (Annual)32.94%
Month-to-Date Return-1.65%
Cash Flow / Share (TTM)$13.94
EBITD / Share (Annual)$17.00
EPS Growth (3Y)6.12%
Operating Margin (Annual)34.77%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)30.78x
ROI (5Y Avg)16.60%
P/E Excl Extra (TTM)28.27x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$15.33
P/TBV (Quarterly)6.31x
P/B Ratio (Annual)6.16x
Inventory Turnover (TTM)1.14x
Pretax Margin (TTM)38.69%
Book Value / Share (Annual)$73.49
Price vs S&P 500 (13W)-2.32%
Net Margin Growth (5Y)-5.50%
Beta0.33x
P/FCF (Annual)34.99x
Revenue / Share (TTM)$46.84
ROE (TTM)22.70%
52-Week Low$362.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.85
4.00
4.05
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VRTXVertex Pharmaceuticals Inc | 9.31x | 8.90% | 86.24% | 8.28% | $439.18 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Vertex Pharmaceuticals is a global biotech company with a dominant position in cystic fibrosis treatments (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) and a diversified pipeline including approved gene-editing therapy Casgevy for blood disorders and Journavx for acute pain. The company is also advancing cell therapies for type 1 diabetes and small-molecule programs targeting APOL1-mediated kidney disease.